{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:56:30Z","timestamp":1792637790193,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jad.2024.01.262","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T17:40:24Z","timestamp":1706636424000},"page":"534-540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine\/esketamine"],"prefix":"10.1016","volume":"351","author":[{"given":"Balwinder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Vande Voort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa K.","family":"Pazdernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.01.262_bb0005","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","article-title":"Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study","volume":"175","author":"Canuso","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0010","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCP.0000000000001465","article-title":"Esketamine nasal spray for the rapid reduction of depressive symptoms in major depressive disorder with acute suicidal ideation or behavior","volume":"41","author":"Canuso","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.01.262_bb0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.euroneuro.2006.04.008","article-title":"The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures","volume":"16","author":"Carmody","year":"2006","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.01.262_bb0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2006.03.024","article-title":"Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS","volume":"95","author":"Carmody","year":"2006","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.262_bb0025","first-page":"1","article-title":"Suicide and homicide death rates among youth and young adults aged 10-24: United States, 2001-2021","author":"Curtin","year":"2023","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.jad.2024.01.262_bb0030","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/da.22709","article-title":"Anhedonia is associated with suicidal ideation independently of depression: a meta-analysis","volume":"35","author":"Ducasse","year":"2018","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2024.01.262_bb0035","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.2147\/NDT.S273503","article-title":"Treatment-resistant bipolar depression: therapeutic trends, challenges and future directions","volume":"18","author":"Elsayed","year":"2022","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2024.01.262_bb0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0045","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","article-title":"Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development","volume":"35","author":"Frye","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2024.01.262_bb0050","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19m13191","article-title":"Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I)","volume":"81","author":"Fu","year":"2020","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0055","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1017\/S0033291715002159","article-title":"Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study","volume":"46","author":"Hu","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2024.01.262_bb0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/ijnp\/pyaa068","article-title":"Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: results of a phase 3, double-blind, randomized study (ASPIRE II)","volume":"24","author":"Ionescu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2024.01.262_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ph16081164","article-title":"Efficacy of ketamine with and without lamotrigine in treatment-resistant depression: a preliminary report","volume":"16","author":"Joseph","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jad.2024.01.262_bb0070","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.mayocp.2022.12.020","article-title":"The association between thyroid stimulating hormone and depression: a historical cohort study","volume":"98","author":"Kumar","year":"2023","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jad.2024.01.262_bb0075","doi-asserted-by":"crossref","first-page":"644","DOI":"10.15585\/mmwr.mm7224a1","article-title":"National, state-level, and county-level prevalence estimates of adults aged >\/=18 years self-reporting a lifetime diagnosis of depression - United States, 2020","volume":"72","author":"Lee","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"10.1016\/j.jad.2024.01.262_bb0080","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2021.07.035","article-title":"The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine","volume":"294","author":"McIntyre","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.262_bb0085","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0090","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1017\/S0033291715001506","article-title":"Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial","volume":"45","author":"Murrough","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2024.01.262_bb0095","article-title":"Global, regional, and national burden of suicide mortality 1990 to 2016: systematic analysis for the Global Burden of Disease Study 2016","volume":"364","author":"Naghavi","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2024.01.262_bb0100","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jad.2024.01.003","article-title":"Hypersomnia as a predictor of response to intravenous ketamine\/intranasal esketamine in treatment resistant depression","volume":"349","author":"Patarroyo-Rodriguez","year":"2024","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.262_bb0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jpsychires.2014.09.008","article-title":"Psychometric properties of the 16-item Quick Inventory of Depressive Symptomatology: a systematic review and meta-analysis","volume":"60","author":"Reilly","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2024.01.262_bb0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0115","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0120","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19l12852","article-title":"The association between body mass index and remission rates in patients with treatment-resistant depression who received intravenous ketamine","volume":"80","author":"Singh","year":"2019","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0125","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/14740338.2022.2045272","article-title":"Can ketamine be a safe option for treatment-resistant bipolar depression?","volume":"21","author":"Singh","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2024.01.262_bb0130","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22m14548","article-title":"Comparative effectiveness of intravenous ketamine and intranasal esketamine in clinical practice among patients with treatment-refractory depression: an observational study","volume":"84","author":"Singh","year":"2023","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0135","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.biopsych.2022.10.007","article-title":"Ketamine-associated change in anhedonia and mTOR expression in treatment-resistant depression","volume":"93","author":"Singh","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0140","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jad.2016.09.008","article-title":"Continuation phase intravenous ketamine in adults with treatment-resistant depression","volume":"206","author":"Vande Voort","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2024.01.262_bb0145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0150","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2024.01.262_bb0155","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724002817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724002817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T02:55:10Z","timestamp":1720061710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724002817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"alternative-id":["S0165032724002817"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.01.262","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine\/esketamine","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.01.262","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}